PTX albumin nanoparticles (Abraxane) developed by Celgene use human serum albumin as a carrier, which can be rapidly distributed and aggregated in tumors through the natural transport pathway of albumin (albumin binds to the receptor proteins and the foveal proteins) in vivo to improve the efficacy and reduce the toxicity of chemotherapy.[45] KRAS is the most common mutated gene in human cancers. This evidence concerns the gene ALB and cancer.